Scarica l'app Stockscreener
55.65
0.66%
-0.37
Dopo l'orario di chiusura:
55.65
Precedente Chiudi:
$56.02
Aprire:
$55.75
Volume 24 ore:
2.99M
Relative Volume:
0.97
Capitalizzazione di mercato:
$9.25B
Reddito:
$1.06B
Utile/perdita netta:
$-326.58M
Rapporto P/E:
-26.47
EPS:
-2.1022
Flusso di cassa netto:
$-977.73M
1 W Prestazione:
-4.27%
1M Prestazione:
-2.27%
6M Prestazione:
-26.45%
1 anno Prestazione:
-13.05%
Intervallo 1D:
$54.91
$55.77
Intervallo di 1 settimana:
$52.15
$58.96
Portata 52W:
$50.01
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Nome
Ionis Pharmaceuticals Inc
Settore
Industria
Telefono
(760) 931-9200
Indirizzo
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
55.65 | 9.31B | 1.06B | -326.58M | -977.73M | -2.1022 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2026-04-10 | Ripresa | Raymond James | Outperform |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-10-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2025-09-03 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Neutral |
| 2024-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Ripresa | Jefferies | Buy |
| 2024-06-14 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Strong Buy |
| 2023-07-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-06-07 | Ripresa | Piper Sandler | Overweight |
| 2023-05-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2022-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-31 | Ripresa | Piper Sandler | Overweight |
| 2022-03-01 | Iniziato | Citigroup | Sell |
| 2022-03-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Aggiornamento | UBS | Sell → Neutral |
| 2021-03-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Iniziato | UBS | Sell |
| 2020-12-15 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-09-02 | Iniziato | The Benchmark Company | Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-11-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Reiterato | Stifel | Hold |
| 2018-08-07 | Reiterato | Stifel | Hold |
| 2018-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Ripresa | Goldman | Sell |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-08-09 | Reiterato | Stifel | Hold |
| 2017-03-10 | Downgrade | Goldman | Neutral → Sell |
| 2016-12-28 | Reiterato | BMO Capital Markets | Outperform |
| 2016-12-27 | Reiterato | Leerink Partners | Mkt Perform |
Mostra tutto
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure? - Yahoo Finance
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making. - Yahoo Finance
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue? - Zacks Investment Research
IONS Maintained by Barclays -- Price Target Lowered to $85.00 - GuruFocus
Raymond James cuts Ionis Pharmaceuticals price target on trial miss - Investing.com
Raymond James cuts Ionis Pharmaceuticals price target on trial miss By Investing.com - Investing.com Canada
Raymond James Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $84 - Moomoo
Retatrutide clears BLA bar while Wainua stumbles in busy July for trials - BioWorld News
IONS Maintained by Goldman Sachs -- Price Target Lowered to $56 - GuruFocus
BMO cuts Ionis Pharmaceuticals stock price target on drug failure By Investing.com - Investing.com Canada
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades - Seeking Alpha
Ionis Pharmaceuticals gets $85 price target des... - Pluang
H.C. Wainwright cuts Ionis stock price target to $100 on pelacarsen removal - Investing.com
Canaccord cuts Ionis stock price target to $85 on pelacarsen trial miss - Investing.com
Needham reiterates Ionis stock rating after trial failure By Investing.com - Investing.com India
Ionis Stock Sinks 10% as Analysts Cut Targets After Pelacarsen Trial Miss - TipRanks
IONS Maintained by HC Wainwright & Co. -- Price Target Lowered to $100 - GuruFocus
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Why Is Novartis Stock Falling Today?Novartis (NYSE:NVS), Ionis Pharmaceuticals (NASDAQ:IONS), Royalty - Benzinga
Ionis Pharmaceuticals Shares Fall After Pelacarsen Phase 3 Trial Misses Primary Endpoint - Yahoo Finance
Why is Ionis Pharmaceuticals stock tumbling today? By Investing.com - Investing.com India
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander DiseaseSlideshow (NASDAQ:IONS) 2026-09-07 - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Ionis Drug Wins FDA Approval as First Alexander Disease Treatment - Yahoo
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Evaluating A 51.72% Upside Potential - DirectorsTalk Interviews
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) - BioSpace
Ionis wins FDA approval for Zilganersen to treat Alexander disease - Indian Pharma Post
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines - BioPharma Dive
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $61 to $115 - Moomoo
Novartis’ pelacarsen fails Phase 3 trial, missing cardiovascular risk reduction endpoint - Minichart
Six first-in-class approvals in August - biocentury.com
Novartis, Ionis’ experimental heart drug misses key goal in closely watched trial - WTVB
Novartis, Ionis' experimental heart drug misses key goal in closely watched trial - Reuters
FDA Grants Approval for Ionis Pharmaceuticals' ZANVASTRO to Treat Alexander Disease - Kalkine Media
Royalty Pharma Announces Novartis HORIZON Pelacarsen Trial Results and Updates Return Outlook on Ionis Funding Agreement - quiverquant.com
Ionis Stock Loses $877 Million After Pelacarsen Phase 3 Miss - TechStock²
FDA Approves Ionis Pharma Drug, the First for Ultra-Rare Alexander Disease - MedCity News
Ionis Pharmaceuticals Updates on Novartis Pelacarsen Trial Outcome - TipRanks
Ionis Pharmaceuticals Reports Pelacarsen Phase 3 Lp(a)HORIZON Trial Fails Primary Cardiovascular Endpoint - Kalkine Media
Ionis, Novartis’ key experimental heart drug fails in late-stage trial - 1470 & 100.3 WMBD
Ionis, Novartis' key experimental heart drug fails in late-stage trial - Yahoo Finance
Stocks to Watch : Ionis Pharmaceuticals, Novartis, Corvex - marketscreener.com
Ionis Pharma prices first FDA-approved treatment for Alexander disease at $285,000 per dose - Reuters
Ionis-Novartis heart drug misses main goal of late-stage trial - marketscreener.com
Ionis Wins FDA Nod for First-Ever Alexander Disease Therapy, Priced at $285,000 a Dose - finance.biggo.com
Ionis Pharmaceuticals Price Target Maintained With a $115.00/Share by HC Wainwright & Co. - Moomoo
Ionis: Downgrading To Sell After A Series Of Unfortunate Events (NASDAQ:IONS) - Seeking Alpha
FDA Approves Ionis’s Zanvastro for Alexander Disease - Financial-News.co.uk
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging. - Barron's
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment - Yahoo Finance
Ionis wins FDA clearance for Alexander disease drug, company's first solo neurology approval - Endpoints News
Ionis Pharmaceuticals Inc Azioni (IONS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):